Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome

Chang, Ming Hui; Chou, Jen Wei; Chen, Shan Ming; Tsai, Max; Sun, Yu; Lin, Chun; Lin, Ching Pin

doi:10.3892/mmr.2014.2180

Cited by 55 publications

(52 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one study, FCP levels in IBS patients and healthy control subjects were 44.50 and 35 μg/g, respectively. No statistical difference was identified between the IBS patients and the healthy control subjects . Bonnín Tomàs et al .…”

Section: Discussionmentioning

confidence: 92%

Optimal cut‐off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?

et al. 2018

View full text Add to dashboard Cite

IntroductionThere is variability in the fecal calprotectin (FCP) cut‐off level for the prediction of ulcerative colitis (UC) disease activity and differentiation from irritable bowel disease (IBS‐D). The FCP cut‐off levels vary from country to country.AimsWe aimed to assess FCP as a marker of disease activity in patients with UC. We determined the optimal FCP cut‐off value for differentiating UC and IBS‐D.MethodsIn a prospective study, we enrolled 76 UC and 30 IBS‐D patients. We studied the correlation of FCP with disease activity/extent as well as its role in differentiating UC from IBS‐D. We also reviewed literature regarding the optimal FCP cut‐off level for the prediction of disease activity and differentiation from IBS‐D patients.ResultsSensitivity, specificity, positive predictive value, and negative predictive value of FCP (cut‐off level, 158 μg/g) for the prediction of complete mucosal healing (using Mayo endoscopic subscore) were 90, 85, 94.7, and 73.3%, respectively. Sensitivity, specificity, positive predictive value, and negative predictive value of FCP (cut‐off level, 425 μg/g) for the prediction of inactive disease (Mayo Score ≤ 2) were 94.3, 88.7, 86.2, and 95.4%, respectively. We also found a FCP cut‐off value of 188 μg/g for the differentiation of UC from IBS‐D.ConclusionsThe study reveals the large quantitative differences in FCP cut‐off levels in different study populations. This study demonstrates a wide variation in FCP cut‐off levels in the initial diagnosis of UC as well as in follow‐up post‐treatment. Therefore, this test requires validation of the available test kits and finding of appropriate cut‐off levels for different study populations.

show abstract

Section: Discussionmentioning

confidence: 92%

Optimal cut‐off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…There is a low-grade inflammation of the gut that has been already acknowledged and literature data supports the putative role of the low-grade inflammation in IBS [65][66][67][68]. Several articles addressed this issue, some authors investigated tissue samples [23], while others assessed blood or stool samples [69][70][71][72] in order to detect and determine the inflammation status in IBS patients.…”

Section: Low-grade Inflammationmentioning

confidence: 99%

“…There are already numerous studies that assessed erythrocyte sedimentation rate, C-reactive protein (CRP) from blood sample, fecal calprotectin, and/or lactoferin in order to detect their presence in IBS and/or to calculate their predictive values [71][72][73]. Valuable information was provided by a meta-analysis, although that assessed their cut-off values in order to exclude inflammatory bowel diseases [74].…”

Section: Low-grade Inflammationmentioning

confidence: 99%

Inflammation as a Potential Therapeutic Target in IBS

Chira¹,

Chira²,

Dumitraşcu³

2016

Irritable Bowel Syndrome - Novel Concepts for Research and Treatment

View full text Add to dashboard Cite

The pathogenesis of irritable bowel syndrome (IBS) has been intensively researched, and despite a long journey for unraveling all the structures and the pathways involved, it still remains partially obscure. Inflammation was the first to be hypothesized as a potential pathway for the pathogenesis of IBS. It remains a keystone in the complex machinery of the pathogenesis that is currently considered multifactorial. Elucidating the pathogenesis of IBS is crucial for a targeted therapy of the disease. In this chapter, we review information regarding gut inflammation in IBS, underlining some of the newest data or the cornerstones. Additionally, our aim was also to review treatment currently available and future perspectives regarding anti-inflammatory treatments for IBS. Newer techniques allow detection and research of mediators involved in inflammation, as well as their potential role to be targeted by pharmacological agents. Recent data supports not only further research of the newer agents that are currently being developed but also some of the available ones that do not have sufficient evidence. Emerging therapies that target inflammation are under evaluation, in trials. A multidrug or a multidisciplinary approach needs to be considered in some cases that fail to respond to current treatment.

show abstract

“…Fecal calprotectin levels are correlated with the degree of intestinal inflammation, and have been found to increase when neutrophils migrate into the bowel lumen due to the inflammatory process 2. Therefore, fecal calprotectin could help discriminate between IBD and IBS,3 monitor treatment response and endoscopic disease activity,45 and predict relapse for IBD 6. Studies have also shown that fecal calprotectin levels are correlated with endoscopic severity scores5 and the extent of inflammation in Asian patients with UC 7.…”

mentioning

confidence: 99%

Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?

Shu

2016

Intest Res

View full text Add to dashboard Cite

Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome

Cited by 55 publications

References 19 publications

Optimal cut‐off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?

Optimal cut‐off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?

Inflammation as a Potential Therapeutic Target in IBS

Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?

Contact Info

Product

Resources

About